Genomics of Drug Sensitivity in Cancer |
OSI-930
|
Synonyms |
OSI 930 OSI930
|
Targets |
KIT
|
Target pathway |
RTK signaling
|
PubCHEM ID |
9868037
|
Jsmol |
|
Download molecule |
9868037
|
PUBCHEM IUPAC INCHI |
InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)
|
Smiles |
S3(C(=C(NCC=1(C=2(C(N=CC=1)=CC=CC=2)))C=C3)C(=O)NC4(=CC=C(OC(F)(F)F)C=C4))
|
Cluster number |
98
|
calculated LogS |
-6,25
|
Molecular weight |
443,448
|
calculated LogP |
5,1538
|
H-Acceptors |
5
|
H-Donors |
2
|
Ro5 violations |
1
|
Druglikeness |
-4,8853
|
DrugScore |
0,187191524927602
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,1745
|
Rat Acute Toxicity |
2,5362
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,998
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,7674
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 2C9 Inhibitor |
Inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-4,3521
|